MaxCyte consensus sets USD 6.00 target for MaxCyte stock

Published on 10/20/2026 at 19:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MaxCyte guides to USD 34.00 million for fiscal 2026. MaxCyte stock costs EUR 1.18 on October 20, 2026 at USD 136.7 million value.

Analyst target and reporting date

A six-analyst consensus set a USD 6.00 target for MaxCyte stock on October 20, 2026.
Preliminary core revenue reached USD 8.10 million in the third quarter of 2026, up 26.00 percent year over year.
MaxCyte stock costs EUR 1.18 at Lang & Schwarz on October 20, 2026 at 7:45 p.m. CEST.
MaxCyte will report full third-quarter results on November 10, 2026.

MXCT, US57777K1060, Illustration mit AI erstellt.

A six-analyst consensus placed a USD 6.00 12-month target on MaxCyte stock on October 20, 2026, according to Paasa. The target is 354.55 percent above the USD 1.32 Nasdaq price cited for the same date. MaxCyte was trading at EUR 1.18 at Lang & Schwarz on October 20, 2026 at 7:45 p.m. CEST.

Revenue guidance moved higher

MaxCyte reported preliminary core business revenue of USD 8.10 million for the third quarter ended September 30, 2026, an increase of 26.00 percent from the third quarter of 2025. The company also reported more than USD 1.00 million in Strategic Platform License program revenue, including a USD 1.00 million milestone.

According to the MaxCyte filing dated October 14, 2026, full-year 2026 revenue guidance rose to USD 34.00 million from USD 30.00 million to USD 32.00 million. Core business guidance increased to USD 28.00 million from USD 25.00 million to USD 27.00 million, while Strategic Platform License revenue guidance reached USD 6.00 million from USD 5.00 million.

Price remains below the yearly high

The Nasdaq price was USD 1.32 at 1:46 p.m. EDT on October 20, 2026. The 52-week range was USD 0.64 to USD 1.81, placing the price 27.07 percent below the high. Trading volume stood at 720,414 shares, while the trailing price-to-earnings ratio was negative 3.98.

November 10 is the next date

MaxCyte is scheduled to release full third-quarter results on November 10, 2026, with the earnings call set for 4:30 p.m. Eastern Time, according to the MaxCyte filing. The release will include royalty revenue that was excluded from the preliminary third-quarter disclosure.

Nasdaq valuation remains negative

MaxCyte had a market capitalization of USD 136.7 million on October 20, 2026. Its negative price-to-earnings ratio reflects reported losses rather than a positive earnings base, while the preliminary revenue update supplies the next operating test for the stock.

Price and investor perspective

MaxCyte stock was trading at EUR 1.18 at Lang & Schwarz on October 20, 2026 at 7:45 p.m. CEST. In the United States, the Nasdaq quote was USD 1.32 at 1:46 p.m. EDT on the same date, and the stock stood 27.07 percent below its USD 1.81 52-week high. The further course of trading is shown by the continuously updated real-time quote of MaxCyte stock.